Nano Hospitals
Market Cap
₹21 ₹21.00 Cr.
P/E
0.00
PEG = P/E ÷ 5yr Forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
1.45
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
19.07 %
Institutions
Institutions
-
Market cap
Market cap
21.00 Cr
No. of Shareholders
No. of Shareholders
13,817
OPM (%)
OPM (%)
-207 %
PE
PE
-
Prom Holding
Prom Holding
23.64 %
ROCE (%)
ROCE (%)
-0.33
ROE (%)
ROE (%)
-
Sales
Sales
0.22 Cr
  • Transgene Biotek
  • Nidan Labs. & Health
  • Tejnaksh Healthcare

Nothing to show here

This view can't be shown right now. We're continuously expanding and updating coverage across companies, so please check back again soon.

Nothing to show here

This view can't be shown right now. We're continuously expanding and updating coverage across companies, so please check back again soon.

Price Range

See where the stock is trading versus its 52-week high and low.

Low
2
52W Range
High
5
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

7 Yes

Positive for this company

1 Neutral

Neutral for this company

7 No

Negative for this company

1 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Peer Comparison

FAQs on Transgene Biotek Ltd. Business

Transgene Biotek Ltd specializes in manufacturing drugs including New Drug Delivery Systems, Biogenerics, Human Vaccines, and Cancer Drugs/Oncology. They also offer services in Diagnostics and CRO.

Transgene Biotek major competitors are Nidan Labs. & Health, Tejnaksh Healthcare, Global Longlife Hosp, Chennai Meena Multi, KK Shah Hospitals, Sharma East Hospital, Soni Medicare.
Market Cap of Transgene Biotek is ₹21 Crs.
While the median market cap of its peers are ₹28 Crs.

Transgene Biotek seems to be less financially stable compared to its competitors.
Altman Z score of Transgene Biotek is -3.73 and is ranked 8 out of its 8 competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material